Targazyme

09/28/2022

TargaZyme is a clinical-stage biotechnology company based in San Diego, California that is focused on the research and development of disruptive and novel off-the-shelf T-Cell products aimed at improving T-cell therapy efficacy by delivering more T-cells to tumor sites.

Our goal for a traumatic disease like cancer is to create a CANCER-FREE WORLD; our medicine fights T-cells to eliminate cancer while causing no side effects.

Invest in this life-changing project today at https://www.startengine.com/targazyme/ and receive BONUS SHARES!

09/26/2022

TargaZyme is a clinical-stage biotechnology company based in San Diego, California that is focused on the research and development of disruptive and novel off-the-shelf T-Cell products with the goal of improving the efficacy of T-cell therapies. It also promotes synapse formation between T-cells and tumors, allowing for greater intra-tumor pe*******on and improving T-cell cytotoxicity for increased cancer tumor killing.

Invest in this life-changing project today at https://www.startengine.com/targazyme/ and receive BONUS SHARES!

09/20/2022

Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. The immune system helps your body fight infections and other diseases. It is made up of white blood cells and organs and tissues of the lymph system. Immunotherapy is a type of biological therapy.

Invest in this life-changing project today at https://www.startengine.com/targazyme/ and receive BONUS SHARES!

09/17/2022

In a Phase 2 clinical (human) trial at M D Anderson Cancer Center in Texas,
a single dose of our novel patented medicine TZ101 was shown to improve
the survival of terminally ill cancer patients from 64% post-100 days of transplant
to 78% post-100 days of transplant by preventing various diseases such as
infections, GvHD, hemorrhaging, and stem cell engraftment failure.

Invest in this life-changing project today at https://www.startengine.com/targazyme/ and receive BONUS SHARES!

09/14/2022

TargaZyme is a clinical-stage biotechnology company based in San Diego, California that is focused on the research and development of disruptive and novel off-the-shelf T-Cell products aimed at improving T-cell therapy efficacy by delivering more T-cells to tumor sites.

Our goal for a traumatic disease like cancer is to create a CANCER-FREE WORLD; our medicine fights T-cells to eliminate cancer while causing no side effects.

Invest in this life-changing project today at https://www.startengine.com/targazyme/ and receive BONUS SHARES!

The Next Frontier of Cancer Medicine

09/14/2022

ONLY 12 HOURS LEFT TO INVEST WITH BONUS SHARES!!

A single dose of our novel patented medicines TZ101 and TZ102 was shown to improve the survival of terminally ill cancer patients by 64% to 78% post 100 days of transplant, preventing various diseases such as infections, GvHD, hemorrhaging, and stem cell engraftment failure in Phase 2 Clinical (human) Trials at M D Anderson Center in Texas.

Invest in this life-changing project today at https://www.startengine.com/targazyme/ and receive BONUS SHARES!

The Next Frontier of Cancer Medicine

09/06/2022

A single dose of our novel patented medicines TZ101 and TZ102 was shown to improve the survival of terminally ill cancer patients by 64% to 78% post 100 days of transplant, preventing various diseases such as infections, GvHD, hemorrhaging, and stem cell engraftment failure in Phase 2 Clinical (human) Trials at M D Anderson Center in Texas.

Invest in this life-changing project today at https://www.startengine.com/targazyme/ and receive BONUS SHARES!

09/02/2022

Our mission at TargaZyme is to develop novel off-the-shelf t-cell therapy products that harness the metastatic cancer patients’ own T-cells in the fight against cancer, as a potential alternative to chemotherapy, radiation or radical surgery.

Invest in this life-changing project today at https://www.startengine.com/targazyme/ and receive BONUS SHARES!